Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2018

Open Access 01-12-2018 | Review

CD109 and squamous cell carcinoma

Authors: Ruixia Qi, Fengyun Dong, Qiang Liu, Yoshiki Murakumo, Ju Liu

Published in: Journal of Translational Medicine | Issue 1/2018

Login to get access

Abstract

Squamous cell carcinoma (SCC) is well-known for its high rate of metastasis with poor prognosis. CD109 is a glycosylphosphatidylinositol-anchored cell-surface glycoprotein. Recently, CD109 emerges as a potential biomarker and a therapeutic target for SCCs. Accumulating studies have reported that CD109 is highly expressed in human SCCs of multiple organs, and may contribute to the progression of SCCs. In this review, we summarized the findings on expression pattern of CD109 in SCCs, and discussed the molecular mechanisms underlying the roles of CD109 in pathogenesis of SCCs.
Literature
1.
Thompson LD. Laryngeal dysplasia, squamous cell carcinoma, and variants. Surg Pathol Clin. 2017;10:15–33.CrossRefPubMed
2.
Languino LR, Singh A, Prisco M, Inman GJ, Luginbuhl A, Curry JM, South AP. Exosome-mediated transfer from the tumor microenvironment increases TGFbeta signaling in squamous cell carcinoma. Am J Transl Res. 2016;8:2432–7.PubMedPubMedCentral
3.
Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, Wu XF, Schuh AC. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood. 2002;99:1683–91.CrossRefPubMed
4.
Solomon KR, Sharma P, Chan M, Morrison PT, Finberg RW. CD109 represents a novel branch of the alpha2-macroglobulin/complement gene family. Gene. 2004;327:171–83.CrossRefPubMed
5.
Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip A. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB J. 2006;20:1525–7.CrossRefPubMed
6.
Fyfe CD, Grinter R, Josts I, Mosbahi K, Roszak AW, Cogdell RJ, Wall DM, Burchmore RJ, Byron O, Walker D. Structure of protease-cleaved Escherichia coli alpha-2-macroglobulin reveals a putative mechanism of conformational activation for protease entrapment. Acta Crystallogr D Biol Crystallogr. 2015;71:1478–86.CrossRefPubMedPubMedCentral
7.
Hagiwara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H, Ueda M, Takahashi M. Processing of CD109 by furin and its role in the regulation of TGF-beta signaling. Oncogene. 2010;29:2181–91.CrossRefPubMed
8.
Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, Baker MA. Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood. 1991;77:84–93.PubMed
9.
Giesert C, Marxer A, Sutherland DR, Schuh AC, Kanz L, Buhring HJ. Antibody W7C5 defines a CD109 epitope expressed on CD34+ and CD34− hematopoietic and mesenchymal stem cell subsets. Ann NY Acad Sci. 2003;996:227–30.CrossRefPubMed
10.
Yokoyama M, Ichinoe M, Okina S, Sakurai Y, Nakada N, Yanagisawa N, Jiang SX, Numata Y, Umezawa A, Miyazaki K, et al. CD109, a negative regulator of TGF-beta signaling, is a putative risk marker in diffuse large B-cell lymphoma. Int J Hematol. 2017;105:614–22.CrossRefPubMed
11.
Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N, Takahashi T, Yatabe Y, Murakumo Y, Zhang JM, et al. Expression of CD109 in human cancer. Oncogene. 2004;23:3716–20.CrossRefPubMed
12.
Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, Takahashi M. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int. 2007;57:719–24.CrossRefPubMed
13.
Dong F, Liu F, Yan S, Liu X, Jiang Z, Liu J. Elevated expression of CD109 in esophageal squamous cell carcinoma. Pathol Oncol Res. 2015;21:1273–5.CrossRefPubMed
14.
Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M, Nakamura S, Takahashi M. CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int. 2005;55:165–9.CrossRefPubMed
15.
Dong F, Wang Y, Li L, Wang Y, Liu X, Liu J. CD109 expression is increased in cutaneous squamous cell carcinoma. J Dermatol. 2014;41:947–9.CrossRefPubMed
16.
17.
Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, Ueda M, Takahashi M. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci. 2008;99:1916–23.CrossRefPubMed
18.
19.
Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, Hagikura S, Matsukawa Y, Yoshino Y, Hattori R, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int. 2010;60:735–43.CrossRefPubMed
20.
Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, Inoue Y, Ihn H, Matsumoto Y, Kato M. CD109 expression levels in malignant melanoma. J Dermatol Sci. 2010;57:140–2.CrossRefPubMed
21.
Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, Mii S, Jijiwa M, Enomoto A, Asai N, et al. CD109 expression in basal-like breast carcinoma. Pathol Int. 2008;58:288–94.CrossRefPubMed
22.
Emori M, Tsukahara T, Murata K, Sugita S, Sonoda T, Kaya M, Soma T, Sasaki M, Nagoya S, Hasegawa T, et al. Prognostic impact of CD109 expression in myxofibrosarcoma. J Surg Oncol. 2015;111:975–9.CrossRefPubMed
23.
Emori M, Tsukahara T, Murase M, Kano M, Murata K, Takahashi A, Kubo T, Asanuma H, Yasuda K, Kochin V, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS ONE. 2013;8:e84187.CrossRefPubMedPubMedCentral
24.
Shiraki Y, Mii S, Enomoto A, Momota H, Han YP, Kato T, Ushida K, Kato A, Asai N, Murakumo Y, et al. Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. J Pathol. 2017;243:468–80.CrossRefPubMed
25.
Xu J, Chu T, Jin B, Dong X, Lou Y, Zhang X, Wang H, Zhong H, Shi C, Gu A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell lung cancer. Clin Lung Cancer. 2016;17:309–14.CrossRefPubMed
26.
27.
He Y, Liu J, Zhao Z, Zhao H. Bioinformatics analysis of gene expression profiles of esophageal squamous cell carcinoma. Dis Esophagus. 2017;30:1–8.CrossRefPubMedCentral
28.
Osawa H, Nakajima M, Kato H, Fukuchi M, Kuwano H. Prognostic value of the expression of Smad6 and Smad7, as inhibitory Smads of the TGF-beta superfamily, in esophageal squamous cell carcinoma. Anticancer Res. 2004;24:3703–9.PubMed
29.
Megumi K, Ishigami S, Uchikado Y, Kita Y, Okumura H, Matsumoto M, Uenosono Y, Arigami T, Kijima Y, Kitazono M, et al. Clinicopathological significance of BMP7 expression in esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:2066–71.CrossRefPubMed
30.
Chen B, Li C, Zhang L, Lv J, Tong Y. Screening of biomarkers in cervical squamous cell carcinomas via gene expression profiling. Mol Med Rep. 2015;12:6985–9.CrossRefPubMed
31.
Wesola M, Jelen M. Morphometric differentiation of squamous cell carcinoma and adenocarcinoma of the cervix. Pol J Pathol. 2015;66:410–3.CrossRefPubMed
32.
Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46:S20–6.CrossRefPubMed
33.
Nie XJ, Liu WM, Zhang L. Association of VEGF gene polymorphisms with the risk and prognosis of cutaneous squamous cell carcinoma. Med Sci Monit. 2016;22:3658–65.CrossRefPubMedPubMedCentral
34.
Sunagawa M, Mii S, Enomoto A, Kato T, Murakumo Y, Shiraki Y, Asai N, Asai M, Nagino M, Takahashi M. Suppression of skin tumorigenesis in CD109-deficient mice. Oncotarget. 2016;7:82836–50.CrossRefPubMedPubMedCentral
35.
Spiess PE, Dhillon J, Baumgarten AS, Johnstone PA, Giuliano AR. Pathophysiological basis of human papillomavirus in penile cancer: key to prevention and delivery of more effective therapies. CA Cancer J Clin. 2016;66:481–95.CrossRef
36.
Nazir SA, Heetun M, Walsh JL, Lole Harris BH. Hello, is it SCC you are looking for? Squamous cell carcinoma of the penis presenting as an inguinal mass. Clin Genitourin Cancer. 2016;14:e521–4.CrossRefPubMed
37.
Shinagawa K, Yanamoto S, Naruse T, Kawakita A, Morishita K, Sakamoto Y, Rokutanda S, Umeda M. Clinical roles of interleukin-6 and STAT3 in oral squamous cell carcinoma. Pathol Oncol Res. 2017;23:425–31.CrossRefPubMed
38.
Song HW, Chen C, Shen HX, Ma L, Zhao YL, Zhang GJ, Geng ZM, Wang L. Squamous/adenosquamous carcinoma of the gallbladder: analysis of 34 cases and comparison of clinicopathologic features and surgical outcomes with adenocarcinoma. J Surg Oncol. 2015;112:677–80.CrossRefPubMed
39.
Mghirbi F, Ayadi M, Karray W, Yahyaoui Y, Meddeb K, Mokrani A, Raies H, Chraeit N, Mezlini A. Squamous cell carcinoma of the gallbladder. Transl Gastroenterol Hepatol. 2016;1:78.CrossRefPubMedPubMedCentral
40.
Liu XX, Feng AP, He YM, Li Y, Wu Y, Lian X, Hu F, Li JW, Tu YT, Chen SJ. Association of down-regulation of CD109 expression with up-expression of Smad7 in pathogenesis of psoriasis. J Huazhong Univ Sci Technol Med Sci. 2016;36:132–6.CrossRefPubMed
41.
Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.CrossRefPubMed
42.
Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-beta co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther. 2012;14:R144.CrossRefPubMedPubMedCentral
43.
Lampropoulos P, Zizi-Sermpetzoglou A, Rizos S, Kostakis A, Nikiteas N, Papavassiliou AG. TGF-beta signalling in colon carcinogenesis. Cancer Lett. 2012;314:1–7.CrossRefPubMed
44.
ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci. 2004;29:265–73.CrossRefPubMed
45.
Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad2 to the TGFbeta receptor. Cell. 1998;95:779–91.CrossRefPubMed
46.
Moustakas A, Souchelnytskyi S, Heldin CH. Smad regulation in TGF-beta signal transduction. J Cell Sci. 2001;114:4359–69.PubMed
47.
Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson KW, Buschmann MD, Philip A. The TGF-beta co-receptor, CD109, promotes internalization and degradation of TGF-beta receptors. Biochim Biophys Acta. 2011;1813:742–53.CrossRefPubMed
48.
Zhang YE. Non-Smad signaling pathways of the TGF-beta family. Cold Spring Harb Perspect Biol. 2017;9.
49.
Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF-beta receptors and inhibition of TGF-beta responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem. 2012;113:238–46.CrossRefPubMed
50.
Connolly EC, Akhurst RJ. The complexities of TGF-beta action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol. 2011;12:2138–49.CrossRefPubMedPubMedCentral
51.
Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta. 2009;1792:954–73.CrossRefPubMed
52.
Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL. Distinct endocytic pathways regulate TGF-beta receptor signalling and turnover. Nat Cell Biol. 2003;5:410–21.CrossRefPubMed
53.
Tam BY, Larouche D, Germain L, Hooper NM, Philip A. Characterization of a 150 kDa accessory receptor for TGF-beta 1 on keratinocytes: direct evidence for a GPI anchor and ligand binding of the released form. J Cell Biochem. 2001;83:494–507.CrossRefPubMed
54.
Vorstenbosch J, Nguyen CM, Zhou S, Seo YJ, Siblini A, Finnson KW, Bizet AA, Tran SD, Philip A. Overexpression of CD109 in the epidermis differentially regulates ALK1 versus ALK5 signaling and modulates extracellular matrix synthesis in the skin. J Invest Dermatol. 2017;137:641–9.CrossRefPubMed
55.
Dong F, Cheng Y, Sun Q, Lu W, Zhang G, Li L, Allen TD, Liu J. CD109 is specifically expressed in endothelial cells of cutaneous cavernous haemangioma. Histopathology. 2015;67:133–5.CrossRefPubMed
56.
Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, Philip A. CD109 release from the cell surface in human keratinocytes regulates TGF-beta receptor expression, TGF-beta signalling and STAT3 activation: relevance to psoriasis. Exp Dermatol. 2011;20:627–32.CrossRefPubMed
57.
Chuang CH, Greenside PG, Rogers ZN, Brady JJ, Yang D, Ma RK, Caswell DR, Chiou SH, Winters AF, Gruner BM, et al. Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis. Nat Med. 2017;23:291–300.CrossRefPubMed
58.
Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651–62.CrossRefPubMed
59.
Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005;58:833–8.CrossRefPubMedPubMedCentral
60.
Mii S, Murakumo Y, Asai N, Jijiwa M, Hagiwara S, Kato T, Asai M, Enomoto A, Ushida K, Sobue S, et al. Epidermal hyperplasia and appendage abnormalities in mice lacking CD109. Am J Pathol. 2012;181:1180–9.CrossRefPubMed
61.
Jedlinski A, Garvin S, Johansson AC, Edqvist PH, Ponten F, Roberg K. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc. J Oral Pathol Med. 2017;46:717–24.CrossRefPubMed
62.
Joshi A, Zanwar S, Noronha V, Patil VM, Chougule A, Kumar R, Janu A, Mahajan A, Kapoor A, Prabhash K. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? Onco Targets Ther. 2017;10:1859–63.CrossRefPubMedPubMedCentral
63.
Gonzales CB, De La Chapa JJ, Saikumar P, Singha PK, Dybdal-Hargreaves NF, Chavez J, Horning AM, Parra J, Kirma NB. Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. Oral Oncol. 2016;59:12–9.CrossRefPubMedPubMedCentral
64.
Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118:1173–80.CrossRefPubMed
65.
Zhang JM, Murakumo Y, Hagiwara S, Jiang P, Mii S, Kalyoncu E, Saito S, Suzuki C, Sakurai Y, Numata Y, et al. CD109 attenuates TGF-beta1 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells. Biochem Biophys Res Commun. 2015;459:252–8.CrossRefPubMed
66.
Sakakura H, Murakumo Y, Mii S, Hagiwara S, Kato T, Asai M, Hoshino A, Yamamoto N, Sobue S, Ichihara M, et al. Detection of a soluble form of CD109 in serum of CD109 transgenic and tumor xenografted mice. PLoS ONE. 2014;9:e83385.CrossRefPubMedPubMedCentral
67.
Halvaei S, Daryani S, Eslami SZ, Samadi T, Jafarbeik-Iravani N, Bakhshayesh TO, Majidzadeh AK, Esmaeili R. Exosomes in cancer liquid biopsy: a focus on breast cancer. Mol Ther Nucleic Acids. 2018;10:131–41.CrossRefPubMed
Metadata
Title
CD109 and squamous cell carcinoma
Authors
Ruixia Qi
Fengyun Dong
Qiang Liu
Yoshiki Murakumo
Ju Liu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2018
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-018-1461-3

Other articles of this Issue 1/2018

Journal of Translational Medicine 1/2018 Go to the issue

Research

Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer

Research

High expression of TMEM40 is associated with the malignant behavior and tumorigenesis in bladder cancer

Research

Voltammetric analysis for fast and inexpensive diagnosis of urinary tract infection: a diagnostic study

Research

Association between serum S100A9 levels and liver necroinflammation in chronic hepatitis B

Methodology

A modified method for isolation of human cardiomyocytes to model cardiac diseases

Research

NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits